SmgGDS has recently been recognized to play a role in other disorders such as neurological deficits (Asiri et al., 2020), abnormal vascular branching (Wang et al., 2017), and development of aortic aneurysms (Nogi et al., 2018; Renard, 2018), indicating that the therapeutic targeting of SmgGDS should extend beyond our current efforts focused on cancer. The gene discussed is RAP1GDS1; the disease is cancer.